biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s): BIOAF

Healthcare Biotechnology

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.

TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs

Bullboard Posts

Comment by Sir_Holleron Aug 02, 2015 11:10pm

110 Views

Post# 23984204

RE:Sir Holler

As I said,

"BTI may have much more information than we were given in the last news release concerning various doseing regimes, and how much of the problem remained in the Scarpa study. Those close to BTI may have an advantage."

I don't have the data and am left to wonder.
Has BTI tested other dosing regimes over time?
They should know how much disease is left to be solved in the Scarpa study and if they know other dosing regimes can increase enxymatic activity substantially they could have a much clearer picture than we were given. Those close to BTI may have an advantage we don't have.

Bullboard Posts

Three micro-cap value stocks trading at peak pessimism